Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Sagacious99 Mar. 14 at 8:58 PM

$CTMX BTD will be announced on Monday!

1 · Reply

Sagacious99 Mar. 14 at 6:57 PM

$CTMX ORR and PFS increased!!! Blockbuster drug!!! Buyout!!

1 · Reply

Mavi93 Mar. 14 at 5:50 AM

$CTMX There was no reaction last Friday, 09.05.25, shortly before the first data was scheduled to be released the following Monday. Last year, a Monday before the market opened was also chosen to publish the data. At that time, the stock rose by nearly 40% in premarket trading, which was a signal of strong results. We will see what happens on Monday. Good luck to everyone involved!

0 · Reply

olebrun11 Mar. 13 at 7:49 PM

$CTMX somebody know something

0 · Reply

induscapital Mar. 13 at 7:20 PM

$CTMX $1 or below or Double digits coming week.. Monday morning

1 · Reply

Gator5326 Mar. 13 at 6:57 PM

$CTMX Financials scheduled for Monday not data

1 · Reply

Turdsniffer Mar. 13 at 6:46 PM

$CTMX daddy please

0 · Reply

justiceforb_85 Mar. 13 at 5:13 PM

$CTMX not the most encouraging movement going into data release Monday but will add to my position as I do think there is a decent likelihood for decent data on CX-2051.

2 · Reply

PleadNoContest Mar. 13 at 4:09 PM

$CTMX

0 · Reply

Rox22 Mar. 13 at 12:05 AM

$CTMX I’m showing 3 mil in volume today with multiple platforms. Seems all is “normal” running into a potential data release with big world oil events testing market.

0 · Reply

CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

Feb 4, 2026, 8:00 AM EST - 5 weeks ago

CytomX Therapeutics to Present at Upcoming February Conferences

Jan 27, 2026, 7:00 AM EST - 6 weeks ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CRDF

Jan 21, 2026, 3:00 PM EST - 7 weeks ago

Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics

Jan 14, 2026, 2:36 PM EST - 2 months ago

CytomX Therapeutics, Inc. (CTMX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 8:00 AM EST - 2 months ago

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

Dec 15, 2025, 1:46 AM EST - 3 months ago

CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling

Nov 25, 2025, 8:00 AM EST - 3 months ago

CytomX Therapeutics to Present at Upcoming December Investor Conferences

Nov 18, 2025, 9:32 AM EST - 4 months ago

CytomX Therapeutics: Leaning Into The Hype, But What's Next?

Nov 13, 2025, 8:00 AM EST - 4 months ago

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 11, 2025, 4:04 AM EST - 4 months ago

Targeting Adhesion Molecules With ADC's: The Bet Of CytomX

Nov 7, 2025, 2:26 PM EST - 4 months ago

CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:10 PM EST - 4 months ago

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 3:15 PM EST - 4 months ago

Top Biotech Stocks Riding The Rally

GRAL GRFS INCY

Nov 4, 2025, 9:15 AM EST - 4 months ago

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2025, 8:00 AM EDT - 4 months ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 20, 2025, 4:05 PM EDT - 5 months ago

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Oct 13, 2025, 11:45 PM EDT - 5 months ago

CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible

Oct 12, 2025, 5:00 AM EDT - 5 months ago

Renewed Tariff Fears Spotlight Top Performing Stocks Since April

NVDA PSIX SMH VSAT

Oct 6, 2025, 11:20 AM EDT - 5 months ago

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure

Sep 10, 2025, 4:26 PM EDT - 6 months ago

CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 7 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 7 months ago

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Aug 8, 2025, 6:10 PM EDT - 7 months ago

CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:05 PM EDT - 7 months ago

CytomX Therapeutics: Updated Outlook For Late 2025

Aug 7, 2025, 4:10 PM EDT - 7 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 8 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 29, 2025, 8:00 AM EDT - 10 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 10 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 10 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 10 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 10 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 10 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 10 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 10 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 11 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 11 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 1 year ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 1 year ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

Sagacious99 Mar. 14 at 8:58 PM

$CTMX BTD will be announced on Monday!

1 · Reply

Sagacious99 Mar. 14 at 6:57 PM

$CTMX ORR and PFS increased!!! Blockbuster drug!!! Buyout!!

1 · Reply

Mavi93 Mar. 14 at 5:50 AM

0 · Reply

olebrun11 Mar. 13 at 7:49 PM

$CTMX somebody know something

0 · Reply

induscapital Mar. 13 at 7:20 PM

$CTMX $1 or below or Double digits coming week.. Monday morning

1 · Reply

Gator5326 Mar. 13 at 6:57 PM

$CTMX Financials scheduled for Monday not data

1 · Reply

Turdsniffer Mar. 13 at 6:46 PM

$CTMX daddy please

0 · Reply

justiceforb_85 Mar. 13 at 5:13 PM

$CTMX not the most encouraging movement going into data release Monday but will add to my position as I do think there is a decent likelihood for decent data on CX-2051.

2 · Reply

PleadNoContest Mar. 13 at 4:09 PM

$CTMX

0 · Reply

Rox22 Mar. 13 at 12:05 AM

$CTMX I’m showing 3 mil in volume today with multiple platforms. Seems all is “normal” running into a potential data release with big world oil events testing market.

0 · Reply

MicahbRr Mar. 12 at 11:06 PM

$CTMX greetings my friend, long time no see! Feeling very bullish about the next few months. In the short term however, I wanted to see everyone’s opinion on that closing/late-session volume we just had all of a sudden. Almost 6mil at market close😳.

2 · Reply

Gator5326 Mar. 12 at 12:09 PM

$CTMX not sure anything will move up in this market. Iran hitting ships in the straight is not good. GLTA

2 · Reply

Rox22 Mar. 12 at 12:36 AM

$CTMX clearly no one cares about their earnings. Only about the data. Nice attempt at trolling.

1 · Reply

Turdsniffer Mar. 11 at 7:58 PM

$CTMX friday action will be telling. Cant wait !!

1 · Reply

PleadNoContest Mar. 11 at 7:19 PM

$CTMX This ticker is going to do what most others did. Earning will be slightly positive. Not by much. But it will tank. Some algo is just waiting to drive the PPS into the ground.

1 · Reply

bryantboy99 Mar. 11 at 2:23 PM

$CTMX wonder if we'll hear anything on CX-908 which is another pre-clinical interest?

1 · Reply

bryantboy99 Mar. 11 at 2:14 PM

$CTMX place your bets for tomorrow morning. https://ir.cytomx.com/events/event-details/cytomx-therapeutics-fourth-quarter-2025-financial-results

1 · Reply

Bionco Mar. 11 at 11:02 AM

$CTMX Institutional ownership of CTMX increased by ~ 6.6 m shares quarter over quarter, even though Tang Capital completely exited its 11 m share position. Fidelity remains the largest shareholder, now holding 24.688 m shares, representing a 60% increase compared with the previous quarter. Tang’s exit does not necessarily signal a bearish view, while Fidelity’s growing stake reinforces its conviction in the company. Different investors have their own investment strategies..

2 · Reply

SMARTR8 Mar. 10 at 6:55 PM

$MGNX wanna know a secret? This is not retail driving price higher. Remember $CTMX? 💯✅️

0 · Reply

BillionerOfKing Mar. 10 at 6:34 PM

$CTMX Current Stock Price: $4.95 Contracts to trade: $5.0 CTMX Mar 20 2026 Call Entry: $1.40 Exit: $2.71 ROI: 94% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Bionco Mar. 10 at 3:13 PM

$CTMX retail traders are bracing for the binary event....

0 · Reply

BigWangGang Mar. 9 at 8:58 PM

$CTMX when will this be $20?

1 · Reply

Market Cap	792.96M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	11.70
Forward PE	N/A
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	2,864,900
Avg Vol	3,132,732
Day's Range	N/A - N/A
Shares Out	169.44M
Stochastic %K	18%
Beta	2.44
Analysts	Strong Sell
Price Target	$9.00